GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)

Triple combinations of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators demonstrate enhanced clinical efficacy in CF patients with F508del mutation, compared with modest effects of dual combinations. GLPG2737 was developed as a novel corrector for triple combination therapy.

Source: Journal of Cystic Fibrosis - October 4, 2019 Category: Respiratory Medicine Authors: Silke van Koningsbruggen-Rietschel, Katja Conrath, Rainald Fischer, Sivagurunathan Sutharsan, Axel Kempa, Wolfgang Gleiber, Carsten Schwarz, Andreas Hector, Nancy Van Osselaer, Arian Pano, Sam Corveleyn, Dieudonn é Bwirire, Eva Santermans, Karine Muller, Source Type: research